Our latest paper in collaboration with Pfizer on the role of OCT2/MATE in creatinine clearance is accepted in JPET.
Principal Scientist, Head of Retina Assay Development
Dr Carolina Gandara joined Newcells Biotech in January 2020 to accelerate the development and validation of new assays for the Retina platform. Carolina is a molecular biologist with a strong interest in innovation and translational research.
Before joining Newcells Biotech, Carolina was awarded the FPI doctorate fellowship from the Spanish Government to investigate alternative DNA repair pathways in bacteria. Following her PhD, Carolina completed four years of post-doctoral research at Newcastle University, where she was part of a multi-disciplinary team under a £10M Innovative Engineering for Health Award, funded by the Wellcome Trust and the Engineering and Physical Sciences Research Council (EPSRC). Her focus was to develop and validate a gene therapy to be applied with a cortical implant for optogenetic neural control as treatment for patients with focal epilepsy.
She is now Principal Scientist and Head of Retina Assay Development at Newcells. Her expertise in assay development and gene therapy have enabled the design of bespoke projects to meet our customers’ needs as well as R&D projects with the aim to improve the quality of our products and services.